Homology Medicines (BATS:FIXX) CFO Lee Kalowski Sells 3,972 Shares of Stock

Homology Medicines, Inc. (BATS:FIXX) CFO Lee Kalowski sold 3,972 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the completion of the sale, the chief financial officer owned 138,471 shares in the company, valued at $2,293,079.76. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Homology Medicines Price Performance

BATS:FIXX traded down $0.16 on Thursday, reaching $12.73. 978 shares of the stock traded hands, compared to its average volume of 1,230. Homology Medicines, Inc. has a 1-year low of $12.02 and a 1-year high of $14.30.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.